
Over its two years of operation, HubPharm Africa has demonstrated that medication adherence is possible when patients have consistent access to the medicines they need, particularly hard-to-source specialty medicines in underserved and hard-to-reach communities. In an interview, the CEO of HubPharm Africa, Pharm. Sesan Kareem, identified two major factors contributing to mortality among patients living with chronic conditions, which are limited access to medicines and financial constraints. Since its launch in 2024, HubPharm Africa has sought to address these challenges through infrastructure dedicated to chronic care, a diaspora-funded payment channel, and an AI-powered health companion on WhatsApp. According to Kareem, the healthcare delivery company has supplied more than 400,000 medicine packs to over 10,200 active chronic-care patients, helping to bridge gaps in access to essential medicines. He also highlighted the company’s efforts to provide clinicians and pharmacists with patient medication-adherence data, an area he described as a longstanding gap in chronic disease management. In this interview, Kareem discusses the challenges facing patients with chronic conditions, the role of medication accessibility and affordability in improving health outcomes, and how HubPharm Africa is using technology and innovative financing to strengthen continuity of care.
Read the full interview below.
Congratulations on your 2nd anniversary at HubPharm. Briefly share with us how the journey has been from inception till now.
The honest answer is that it has been two years of building something Nigeria did not have a template for.
We started with a simple, painful observation: patients were not dying because medicines did not exist, they were dying because the medicines never reached them consistently. A man with ADHD gets a prescription, fills it once, cannot find the brand the next month, cannot afford it the month after, and by the sixth month, he has quietly stopped. That gap between prescription and sustained access is where African lives are being lost, and nobody owned it.
So we did not build another pharmacy or another delivery app. We built infrastructure for chronic care: PCN-licensed sourcing, cold-chain logistics, clinical pharmacist-led programmes, a diaspora-funded payment channel, and Afiya, our AI health companion on WhatsApp.
The early days were unglamorous. We were sourcing single packs for individual patients, driving deliveries ourselves, and explaining a model that did not fit anyone’s existing category. Today we serve over 10,200 active chronic care patients, we have delivered more than 400,000 medicine packs, we run 10 clinical programmes across sickle cell, cancer, diabetes, cardiology, mental health, HIV and hepatitis, autoimmune and rare conditions, and we have delivered to over 33 states in Nigeria.
Revenue grew 350 per cent year on year and we now employ 15 people directly. Being named a Tony Elumelu Entrepreneur in 2024 and a NASDAQ 2026 finalist validated the model externally, but the internal validation matters more: patients who have stayed on therapy for two years straight.
In what ways can you say HubPharm has impacted patients and practitioners?
For patients, the impact is measurable and clinical, not cosmetic. We have improved medication adherence by 42 per cent across our chronic care cohort, we maintain a 95 per cent patient satisfaction rate, and we have touched over 180,000 lives when you count our screening, education and Afiya interactions. Afiya alone now handles more than 200,000 patient interactions monthly, in over 50 languages, across 35 countries.
What that means in practice is a sickle cell patient in Ilorin gets hydroxyurea on the same day every month instead of hunting for it. It means a cancer patient whose family abroad can fund treatment directly through our diaspora channel instead of wiring money and hoping. It means a diabetic patient receiving a refill reminder, an adherence check and a pharmacist call before the crisis, not after it.
For practitioners, we have deliberately positioned ourselves as an extension of the clinician, never a replacement. Physicians and hospitals refer patients to us for hard-to-source specialty medicines and then receive adherence data back, which closes a loop that has always been open in Nigerian practice. Our institutional agreement with AVON HMO extends that to managed care.
For pharmacists specifically, this is the part I am most proud of. We have created roles where pharmacists practise as clinicians: running therapeutic programmes, doing medication therapy management, counselling patients, and interpreting adherence data. Our profession has been boxed into dispensing for too long. HubPharm is one demonstration that the Nigerian pharmacist can sit at the centre of chronic disease management and be paid for that clinical value.
What are the challenges encountered so far, and how do you hope to overcome them?
Four dominate.
- Financing of care. Over 80 per cent of Nigerian health spending is out of pocket, and chronic disease is a recurring monthly cost. Many patients ration doses not out of ignorance but out of arithmetic. Our response is to diversify who pays: HMO and corporate contracts, employer-sponsored chronic care, our diaspora-funded channel where families abroad pay for care at home, and donor-funded programme partnerships.
2. Foreign exchange and supply volatility. Most specialty medicines are imported and priced in dollars. Naira volatility can wipe out a margin between order and delivery. We are managing this through direct manufacturer and importer relationships, forward purchasing on high-volume lines, tighter inventory discipline, and early conversations on local licensing and fill-finish partnerships.
3. Capital. African health infrastructure is judged by investors against consumer tech timelines. Building trust with a chronic care patient takes years, not weeks. We are addressing this with a blended approach: re-investing our profit into the business, alongside international grant funding from partners interested in access outcomes rather than quick exits.
4. Talent and trust. Retaining clinical talent in a japa economy is real, and so is patient skepticism about counterfeit medicines. On talent, we compete on mission, ownership and clinical growth rather than salary alone. On trust, our answer is verifiable provenance: licensed sourcing, PCN compliance, cold chain integrity, and full traceability on every pack.
None of these are solved. But each of them is now a system we manage rather than a surprise that manages us.





